Clinical Trials
18 trialsNCT04633239 2026-05-22
Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT05768139 2026-05-22
PIKALO-1
Eli Lilly and Company
Phase 1/2 Recruiting
NCT07209449 2026-05-22
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06188520 2026-05-11
CYCAD-1
AstraZeneca
Phase 1/2 Recruiting
NCT05872204 2026-05-05
ALEPRO
Universitaire Ziekenhuizen KU Leuven
Phase 2 Recruiting
NCT06630325 2026-04-28
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT04486352 2026-04-01
EndoMAP
Alliance Foundation Trials, LLC.
Phase 1/2 Recruiting
NCT05735080 2026-04-01
INX-315-01
Incyclix Bio
Phase 1/2 Recruiting
NCT04931342 2026-03-10
BOUQUET
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT04393285 2026-03-09
Abemaciclib and Letrozole to Treat Endometrial Cancer
GOG Foundation
Phase 2 Active not recruiting
NCT06366347 2026-02-11
ALPINE: Maintenance Letrozole/Abemaciclib
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05867251 2025-11-19
Study of AVZO-021 in Patients With Advanced Solid Tumors
Avenzo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT04049227 2025-10-20
Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer
Northwestern University
Phase EARLY_PHASE1 Completed
NCT04469764 2025-07-29
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT03675893 2025-06-15
RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT04188548 2025-06-04
EMBER
Eli Lilly and Company
Phase 1 Active not recruiting
NCT06594679 2025-03-28
NICHOL
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 1/2 Recruiting
NCT03339843 2024-03-15
MiMe-A
Jules Bordet Institute
Phase 2 Completed